Valdman Alexander, Nordenskjöld Agneta, Fang Xiaolei, Naito Ayako, Al-Shukri Salman, Larsson Catharina, Ekman Peter, Li Chunde
Urology Research Laboratory, Cancer Centrum Karolinska, Karolinska Hospital, SE-171 76, Stockholm, Sweden.
Int J Oncol. 2003 May;22(5):1003-7.
Previous studies in hereditary and sporadic prostate cancer have indicated the existence of a tumor suppressor gene in chromosomal region 19p13. The BRG1 gene in this region is one of the possible candidates, based on both the frequency of inactivating mutations in human cancer cell lines, including the prostate cancer cell line DU145, and its functional properties. To our knowledge, no studies have been done to evaluate possible involvement of the BRG1 gene in clinical prostate cancer. To accomplish this, we carried out a complete mutation analysis of all 35 BRG1 exons in tumor and constitutional DNA samples from 21 prostate cancer patients. We report the absence of somatic mutations in the panel of samples employed, but the existence of five germline single nucleotide polymorphisms (SNPs) in CpG islands of the BRG1 gene, among them, three novel ones. In conclusion, the study excludes the presence of common BRG1 mutations in prostate cancer.
先前针对遗传性和散发性前列腺癌的研究表明，在染色体区域19p13存在一个肿瘤抑制基因。基于包括前列腺癌细胞系DU145在内的人类癌细胞系中失活突变的频率及其功能特性，该区域的BRG1基因是可能的候选基因之一。据我们所知，尚未开展研究评估BRG1基因在临床前列腺癌中的可能作用。为实现这一目的，我们对来自21例前列腺癌患者的肿瘤和基因组DNA样本中的所有35个BRG1外显子进行了全面的突变分析。我们报告在所采用的样本组中不存在体细胞突变，但在BRG1基因的CpG岛中存在五个种系单核苷酸多态性（SNP），其中三个是新发现的。总之，该研究排除了前列腺癌中存在常见BRG1突变的可能性。
